To ask the Secretary of State for Health and Social Care, how many cancer-related clinical trials have been (a) cancelled and (b) suspended as a result of the covid-19 outbreak.
During the COVID-19 outbreak, Medicines and Healthcare products Regulatory Agency (MHRA) guidance requires trial sponsors to notify the MHRA of a temporary halt to a clinical trial when it involves a direct participant safety issue or a medicines supply issue. Trials which end prematurely are required to be notified to the regulator within 15 days of the decision to end the study.
From 1 March 2020 to 22 April 2020 the MHRA has been notified of 10 temporary halts to cancer-related trials of investigational medicinal products which specifically state COVID-19 as the reason for halting. No cancer-related trials of investigational medicinal products were prematurely ended as a result of COVID-19 during this time. It should be noted that end of trial notifications are only required to be submitted to the regulator if the trial has ended in all the territories it was running in.